NCT07697586 — NSCLC trial site landscape

Public-registry site landscape for NCT07697586, “SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer”, a NSCLC study sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT07697586 (registry record)
Study title	SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
Official title	A Phase II Clinical Study to Evaluate Sacituzumab Tirumotecan (SKB264) in Combination With SKB118 for the Treatment of Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sponsor	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Condition(s)	NSCLC
Phase	PHASE2
Listed sites	2
Site countries	China

Recruiting-density context

At Jilin Cancer Hospital — one of the facilities listed on this trial — 46 other studies are actively recruiting NSCLC patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.

Patient-friendly overview of this study: eichor.com/study/NCT07697586.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT07697586 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →